Hallandale Pharmacy
Pharmcore, Inc. · Fort Lauderdale, FL · operating since 2004
We do not sell medication and we have no commercial relationship with Hallandale Pharmacy. Everything below is either published by a regulator or published by the pharmacy about itself, labelled as such and dated. We give you the official lookups rather than asking you to take our word for the current position.
The short answer
- Hallandale Pharmacy is the trading name of Pharmcore, Inc., based in Fort Lauderdale, FL. Regulators file under the legal name, so search that.
- Registration: 503A. Hallandale describes itself as "a 503A designated pharmacy" on its own quality page. It does not appear as a registered 503B outsourcing facility, which means its compounding is patient-specific and overseen by the Florida Board of Pharmacy rather than inspected by FDA under outsourcing-facility rules.
- FL licence PH28017: status "Clear", expiring February 28, 2027, no discipline on file as of July 29, 2026.
- FDA warning letter: 605569 (March 11, 2020). Read the dates and which site each one covers — both are material.
- Compounded semaglutide and tirzepatide are NOT FDA-approved as finished products, whichever pharmacy prepares them. FDA does not review them for safety, effectiveness or manufacturing quality.
Registration and licence
Hallandale describes itself as "a 503A designated pharmacy" on its own quality page. It does not appear as a registered 503B outsourcing facility, which means its compounding is patient-specific and overseen by the Florida Board of Pharmacy rather than inspected by FDA under outsourcing-facility rules.
- Licence number
- PH28017
- Status
- Clear
- Qualifications
- Special Sterile Compounding
- Expires
- February 28, 2027
- Discipline on file
- No
Accreditation the pharmacy claims
- PCAB (Pharmacy Compounding Accreditation Board) — stated by Hallandale on its own site
We report this as the pharmacy's own statement. We have not independently confirmed it, and we are not endorsing it.
Regulatory record
Every item below is a public document, linked to its source, with the date it was issued and the dates of any inspection behind it. Where the agency recorded the company's response, a completed recall, or which legal entity a record actually concerns, that is included — leaving it out would misrepresent the record. Where the company has answered publicly, its answer is printed too.
- FDA Form 483 (observations)Form 483 issued to Pharmcore Inc. dba Hallandale Pharmacy
From an inspection running 2025-06-03 to 2025-06-13.
Investigator observations at the Fort Lauderdale facility included a wipe being taken from the ISO-7 area into the ISO-5 space while opened vials were present, and smoke studies that did not simulate routine production with the equipment actually used in the ISO-5 area.
Context FDA published with it: A Form 483 is a list of an investigator’s observations at the close of an inspection. It is not a finding of violation and it is not a warning letter. Firms respond to 483s and many are resolved without further action.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov - FDA warning letter605569
From an inspection running 2018-07-02 to 2018-07-13.
FDA found that some products did not meet the conditions of section 503A — specifically that valid prescriptions for individually identified patients had not been received for a portion of what was produced — and recorded serious deficiencies in the firm’s practices for producing sterile drug products.
Context FDA published with it: The inspection was of the old facility at 1109 East Hallandale Beach Boulevard, Hallandale. In the same letter FDA acknowledges the firm’s response, its voluntary recall begun 2 August 2018, that it ceased sterile compounding at that site on 6 July 2018, and that it began sterile compounding in August 2018 at the Fort Lauderdale facility it operates now. The letter therefore concerns a site the company had already left.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov
What it compounds for GLP-1 patients
- · Compounded semaglutide
- · Compounded tirzepatide
Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products. FDA does not review them for safety, effectiveness or manufacturing quality before they reach patients. That applies to every compounded GLP-1 regardless of which pharmacy prepares it, and it is a separate question from whether the pharmacy is licensed.
If you would rather not take that trade, the FDA-approved oral products now start at $149/month direct from their manufacturers — see the cheapest routes compared.
Check it yourself
Search under the legal name — Pharmcore, Inc. — not the brand. Regulators file under the legal entity, and searching the trading name alone is how records get missed.
- FDA — Registered Outsourcing Facilities (503B)
The authoritative list of pharmacies registered with the FDA as 503B outsourcing facilities (the higher-oversight compounding tier). If a pharmacy claims to be 503B, it should appear here.
- FDA — 503A vs 503B explainer
What the two compounding categories mean: 503A = patient-specific prescriptions under state board oversight; 503B = larger-batch outsourcing facilities under direct FDA cGMP inspection.
- FDA — Warning Letters search
Search the FDA’s public warning-letter database by company name to see whether a pharmacy has an open compliance action. Confirm the date and status — letters can be resolved.
- NABP — Verify a pharmacy / .pharmacy
The National Association of Boards of Pharmacy tools flag rogue online pharmacies and list accredited ones. Legitimate US pharmacies are licensed by a state board.
- LegitScript — Certification lookup
LegitScript certifies healthcare merchants that meet legal + safety standards. Many reputable telehealth GLP-1 providers display a LegitScript badge you can verify here.
- Your state Board of Pharmacy
Every US pharmacy must be licensed by the state board where it operates (and often where it ships). State boards publish license status + disciplinary history.
Questions people ask about Hallandale Pharmacy
Is Hallandale Pharmacy a licensed pharmacy?
The FL board of pharmacy lists licence PH28017 with status "Clear", carrying the Special Sterile Compounding qualification, expiring February 28, 2027. The board record shows no discipline on file and no public complaint. Licence status changes, so confirm it yourself at the board's lookup before relying on it. Verified July 29, 2026.
What is the regulatory record for Hallandale Pharmacy?
FDA issued warning letter 605569 on March 11, 2020, following an inspection running 2018-07-02 to 2018-07-13. FDA found that some products did not meet the conditions of section 503A — specifically that valid prescriptions for individually identified patients had not been received for a portion of what was produced — and recorded serious deficiencies in the firm’s practices for producing sterile drug products. The inspection was of the old facility at 1109 East Hallandale Beach Boulevard, Hallandale. In the same letter FDA acknowledges the firm’s response, its voluntary recall begun 2 August 2018, that it ceased sterile compounding at that site on 6 July 2018, and that it began sterile compounding in August 2018 at the Fort Lauderdale facility it operates now. The letter therefore concerns a site the company had already left. Our check on July 29, 2026 did not surface a published close-out letter, which means we did not find one — not that none exists.
Is a Form 483 the same as a warning letter?
No, and the difference matters. A Form 483 is the list of observations an FDA investigator leaves at the end of an inspection. It records what the investigator saw, not an agency finding that the law was broken. A warning letter comes later and states FDA's position that violations occurred. Firms respond to 483s and many are resolved without a warning letter ever being issued.
Does Hallandale Pharmacy make FDA-approved GLP-1 medication?
No compounding pharmacy does. Hallandale Pharmacy publicly compounds compounded semaglutide and compounded tirzepatide. Compounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or manufacturing quality before they reach patients. That is true of every compounded product regardless of which pharmacy prepares it, and it is a different thing from the pharmacy being licensed or unlicensed.
How do I check Hallandale Pharmacy myself?
Three free lookups settle it: the FDA warning-letter database, searched by the legal name (Pharmcore, Inc.) rather than the trading name; the FDA list of registered 503B outsourcing facilities, if the pharmacy claims 503B status; and your state board of pharmacy's licence verification. All three are linked at the bottom of this page. Check the legal name — regulators file under it, and searching the brand alone misses records.